Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VY1706 in early Alzheimer's Disease
NCT07764146Phase 1Recruiting
- Sponsor
- Voyager Therapeutics
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of VY1706 in Alzheimer's disease (AD) (3 arms), sponsored by Voyager Therapeutics. Primary endpoint: Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures at 52 weeks. Started Sep 2026; status: recruiting.
02
Drugs
VY1706
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07764146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764146.